209 related articles for article (PubMed ID: 2949833)
1. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
[TBL] [Abstract][Full Text] [Related]
2. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.
Peppoloni S; Herberman RB; Gorelik E
Cancer Res; 1985 Jun; 45(6):2560-6. PubMed ID: 2580624
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of anti-Pichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2.
Walker CM; Paetkau V; Rawls WE; Rosenthal KL
J Immunol; 1985 Aug; 135(2):1401-7. PubMed ID: 2989365
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
8. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).
Tentori L; Leonetti C; Lozupone F; Bonmassar E
Cancer Immunol Immunother; 1995 Dec; 41(6):375-83. PubMed ID: 8635195
[TBL] [Abstract][Full Text] [Related]
9. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
10. Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Tabi Z; Allan JE; Ceredig R; Doherty PC
Immunology; 1988 Mar; 63(3):423-9. PubMed ID: 2895062
[TBL] [Abstract][Full Text] [Related]
11. T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide.
Diamantstein T; Willinger E; Reiman J
J Exp Med; 1979 Dec; 150(6):1571-6. PubMed ID: 159940
[TBL] [Abstract][Full Text] [Related]
12. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
13. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
14. Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assay.
Simcik W; Sheu TL; LeGrue SJ
Cancer Immunol Immunother; 1989; 30(4):219-26. PubMed ID: 2598191
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
17. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro.
Varkila K; Hurme M
Immunology; 1983 Mar; 48(3):433-8. PubMed ID: 6219062
[TBL] [Abstract][Full Text] [Related]
18. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
19. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 induces both, growth and maturation of lectin reactive Lyt-2+ but not Lyt-2-precursor cells and regulates the cytolytic potential of effector cells.
Hochgeschwender U; Diamantstein T; Prester M; Nerz G; Simon MM
Immunobiology; 1986 Apr; 171(3):274-301. PubMed ID: 3086217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
